Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire—Female (SQOL-F), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were completed at baseline and week 12. Tolterodine ER (n = 201; mean ± SD age, 49 ± 12 years) reduced UUI episodes (P = 0.0029), total (P = 0.0006) and OAB (P < 0.0001) micturitions, and pad use per 24 h (P = 0.0024), and was associated with improvements in SQOL-F (P = 0.004), PISQ total (P = 0.009), and HAD Anxiety (P = 0.03) scores versus placebo (n = 210; mean ± SD age, 47 ± 12 years). OAB symptoms improved with tolterodine ER as did the scores of sexual health and anxiety measures in sexually active women with OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P (2006) Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 25:293

    Article  Google Scholar 

  2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315

    Article  PubMed  Google Scholar 

  3. Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R et al (2004) The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7:455–463

    Article  PubMed  Google Scholar 

  4. MacDiarmid S, Rosenberg M (2005) Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 21:1413–1421

    Article  PubMed  Google Scholar 

  5. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR et al (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57:1044–1050

    Article  PubMed  CAS  Google Scholar 

  6. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L (2006) Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97:96–100

    Article  PubMed  Google Scholar 

  7. Stach-Lempinen B, Hakala AL, Laippala P, Lehtinen K, Metsanoja R, Kujansuu E (2003) Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn 22:563–568

    Article  PubMed  Google Scholar 

  8. Stach-Lempinen B, Sintonen H, Kujansuu E (2004) The relationship between clinical parameters and health-related quality of life as measured by the 15D in incontinent women before and after treatment. Acta Obstet Gynecol Scand 83:983–988

    Article  PubMed  Google Scholar 

  9. van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP (2002) The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 90:544–549

    Article  PubMed  Google Scholar 

  10. Chen GD, Lin TL, Hu SW, Chen YC, Lin LY (2003) Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn 22:109–117

    Article  PubMed  Google Scholar 

  11. Kim YH, Seo JT, Yoon H (2005) The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women. Int J Impot Res 17:158–63

    Article  PubMed  CAS  Google Scholar 

  12. Salonia A, Zanni G, Nappi RE, Briganti A, Deho F, Fabbri F et al (2004) Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol 45:642–8 discussion 48

    Article  PubMed  Google Scholar 

  13. Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV (2006) The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin Trial. Am J Obstet Gynecol 195:1730–1735

    Article  PubMed  Google Scholar 

  14. Mehta A, Bachmann G (2008) Premenopausal women with sexual dysfunction: the need for a bladder function history. J Sex Med 5:407–412

    Article  PubMed  Google Scholar 

  15. Handa VL, Harvey L, Cundiff GW, Siddique SA, Kjerulff KH (2004) Sexual function among women with urinary incontinence and pelvic organ prolapse. Am J Obstet Gynecol 191:751–756

    Article  PubMed  Google Scholar 

  16. Coyne KS, Margolis MK, Jumadilova Z, Bavendam T, Mueller E, Rogers R (2007) Overactive bladder and women's sexual health: what is the impact? J Sex Med 4:656–666

    Article  PubMed  Google Scholar 

  17. van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A (2001) Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57:414–421

    Article  PubMed  Google Scholar 

  18. Homma Y, Kawabe K (2004) Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 22:251–256

    Article  PubMed  CAS  Google Scholar 

  19. Kelleher CJ, Reese PR, Pleil AM, Okano GJ (2002) Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 8:S608–S615

    PubMed  Google Scholar 

  20. Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z (2007) Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51:1054–1064

    Article  PubMed  CAS  Google Scholar 

  21. Khullar V, Hill S, Laval K-U, Schiotz HA, Jonas U, Versi E (2004) Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64:269–275

    Article  PubMed  Google Scholar 

  22. Siami P, Seidman LS, Lama D (2002) A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 24:616–628

    Article  PubMed  CAS  Google Scholar 

  23. Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086

    Article  PubMed  Google Scholar 

  24. Coyne K, Tubaro A, Brubaker L, Bavendam T (2006) Development and validation of patient-reported outcomes measures for overactive bladder. Urology 68(suppl 2A):9–16

    Article  PubMed  Google Scholar 

  25. Symonds T, Boolell M, Quirk F (2005) Development of a questionnaire on sexual quality of life in women. J Sex Marital Ther 31:385–397

    Article  PubMed  Google Scholar 

  26. Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C (2001) A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol 184:552–558

    Article  PubMed  CAS  Google Scholar 

  27. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    Article  PubMed  CAS  Google Scholar 

  28. Lutfey KE, Link CL, Rosen RC, Wiegel M, McKinlay JB (2008) Prevalence and correlates of sexual activity and function in women: results from the Boston Area Community Health (BACH) Survey. Arch Sex Behav [Epub ahead of print]:

  29. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD (1999) Urinary incontinence and depression. J Urol 162:82–84

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The study was funded by Pfizer Inc. Editorial support was provided by Colin P. Mitchell, PhD, and Donald G. Buerk, PhD, from Complete Healthcare Communications, Inc., and was funded by Pfizer Inc. ClinicalTrials.gov identifier: NCT00143481

Conflicts of interest

Dr. Rogers has been a consultant and investigator for Pfizer Inc. Dr. Bachman has been a consultant and/or investigator for Bayer, Boeringer Ingelheim, Duramed, Johnson and Johnson, P & G, Pfizer Inc, Novartis, Novo-Nordisc, and Wyeth. Drs. Jumadilova, Morrow, Guan and Bavendam and Mr. Sun are employed by Pfizer Inc.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, MSC10-5580 Albuquerque, NM, 87131, USA

    Rebecca Rogers

  2. University of Medicine and Dentistry of New Jersey-RWJMS, New Brunswick, NJ, USA

    Gloria Bachmann

  3. Pfizer Inc, New York, NY, USA

    Zhanna Jumadilova, Franklin Sun, Jon D. Morrow, Zhonghong Guan & Tamara Bavendam

Authors
  1. Rebecca Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gloria Bachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhanna Jumadilova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franklin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jon D. Morrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhonghong Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tamara Bavendam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca Rogers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rogers, R., Bachmann, G., Jumadilova, Z. et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J 19, 1551–1557 (2008). https://doi.org/10.1007/s00192-008-0688-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-008-0688-6

Keywords

Search

Navigation